What question did this study set out to answer?

The study aims to evaluate the safety, tolerability, and pharmacokinetics of HMBD-002, targeting VISTA in advanced solid tumors.

Abstract CT126: Results of phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors

View Full Paper

Ask AI

Bookmark

Authors

Phase 1 trial evaluates safety and efficacy of HMBD-002 targeting VISTA in advanced solid tumors, suggesting further investigation is needed.

The study aims to evaluate the safety, tolerability, and pharmacokinetics of HMBD-002, targeting VISTA in advanced solid tumors.
Conducted a phase 1, open-label, dose escalation trial
Administered HMBD-002 IV as monotherapy or with pembrolizumab
Utilized a 3+3 design for dose escalation
Monitored safety, tolerability, and preliminary antitumor activity
Enrolled 48 subjects, with 28 receiving HMBD-002 monotherapy
Determined a recommended phase 2 dose of 720mg QW
Observed stable disease in 18% of monotherapy and 25% of combination therapy subjects
Identified 37.5% treatment-related adverse events, with the most common being fatigue, rash, and nausea

Rodon et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Phase 1 trial evaluates safety and efficacy of HMBD-002 targeting VISTA in advanced solid tumors, suggesting further investigation is needed.